Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs

Journal of Managed Care Pharmacy

Volumn 18, Issue 2, 2012, Pages 106-115

  Jung, Kyoungrae ^a   McBean, A Marshall ^b   Kim, Jee Ae ^b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; NICOTINIC ACID PLUS SIMVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; GERIATRICS; HEALTH HAZARD; HUMAN; INTERMETHOD COMPARISON; LOWEST INCOME GROUP; MEDICARE; PRESCRIPTION; SOCIAL STATUS;

EID: 84860753975     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2012.18.2.106     Document Type: Article

References (38)

1. Goldman D, Philipson TJ. Integrated insurance design in the presence of multiple medical technologies. Am Econ Rev. 2007;97(2):427-32.
2. Chandra A, Gruber J, McKnight R. Patient cost-sharing and hospitalization offsets in the elderly. Am Econ Rev. 2010;100(1):193-213. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2982192/?tool=pubmed. Accessed January 25, 2012.
3. Manning WG, Newhouse JP, Duan N, Keeler EB, Leibowitz A. Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev. 1987;77(3):251-77.
4. Cammisa CR, Evans S, Fenter TC, et al. Overview of current Medicare Part D offerings. J Manag Care Pharm. 2008;14(6) (suppl S-C):S4-S7. Available at: http://www.amcp.org/data/jmcp/Aug%20suppl%20C_S4-S7.pdf.
5. Medicare Payment Advisory Commission. Report to the Congress: Medicare payment policy. March 2008. Available at: http://www.medpac.gov/documents/Mar08_EntireReport.pdf. Accessed January 25, 2012.
6. Fairman KA, Curtiss FR. How do seniors respond to 100% cost-sharing for prescription drugs? Quality of the evidence underlying opinions about the Medicare Part D coverage gap. J Manag Care Pharm. 2011;17(5):382-92. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9734.
7. Hoadley J, Hargrave E, Cubanski J, Neuman T. The Medicare Part D coverage gap: costs and consequences in 2007. The Henry J. Kaiser Family Foundation. August 2008. Available at: http://www.kff.org/medicare/upload/7811.pdf. Accessed January 25, 2012.
8. Fung V, Mangione CM, Huang J, et al. Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes. Health Serv Res. 2010;45(2):355-75.
9. Tseng CW, Brook RH, Keeler E, Steers WN, Mangione CM. Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292(8):952-60. Available at: http://jama.ama-assn.org/content/292/8/952.full.pdf+html. Accessed January 25, 2012.
10. Gemmill MC, Thomson S, Mossialos E. What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries. Int J Equity Health. 2008;7:12. Available at: http://www.equityhealthj.com/content/pdf/1475-9276-7-12.pdf. Accessed January 25, 2012.
11. Zhang Y, Lave JR, Donohue JM, Fischer MA, Chernew ME, Newhouse JP. The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products. Med Care. 2010;48(5):409-17.
12. Yin W, Basu A, Zhang JX, Rabbani A, Meltzer DO, Alexander GC. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Ann Intern Med. 2008;148(3):169-77. Available at: http://www.annals.org/content/148/3/169.full.pdf+html. Accessed January 25, 2012.
13. Medicare Payment Advisory Commission. A data book: Medicare Part D program. March 2010. Available at: http://www.medpac.gov/documents/Mar10_PartDDataBook.pdf. Accessed January 25, 2012.
14. Shepherd J, Cobbe SM, Ford I, et al.; for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(20):1301-07. Available at: http://www.nejm.org/doi/full/10.1056/NEJM199511163332001. Accessed January 25, 2012.
15. Downs JR, Clearfield M, Weis S, et al.; for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. JAMA. 1998;279(20):1615-22. Available at: http://jama.ama-assn.org/content/279/20/1615.full.pdf+html. Accessed January 25, 2012.
16. Lloyd-Jones D, Adams R, Carnethon M, et al.; for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480-86. Available at: http://circ.ahajournals.org/content/119/3/e21.full.pdf. Accessed January 25, 2012.
17. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006;12(1):21-28. Available at: http://www.ajmc.com/media/pdf/AJMC_06janGoldman21to28.pdf. Accessed January 25, 2012.
18. Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12 Spec no:SP11-9. Available at: http://www.ajmc.com/media/pdf/AJMC_06DecspeclGibsonSP11.pdf. Accessed January 25, 2012.
19. Medi-Span Master Drug Data Base (MDDB) version 2.5: Wolters Kluwer Health, Inc., Indianapolis, IN; 2010.
20. Pope GC, Kautter J, Ellis RP, et al. Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev. 2004;25(4):119-41. Available at: https://www.cms.gov/HealthCareFinancingReview/downloads/04Summerpg119.pdf. Accessed January 25, 2012.
21. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-74.
22. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care. 2008;46(11):1125-33.
23. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279(18):1458-62. Available at: http://jama.ama-assn.org/content/279/18/1458.full.pdf+html. Accessed January 25, 2012.
24. Benner JS, Glynn RJ, Mogun H, Neuman PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-61. Available at: http://jama.ama-assn.org/content/288/4/455.full.pdf+html. Accessed January 25, 2012.
25. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med. 1997;241(4):317-25. Available at: http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2796.1997.112133000.x/pdf. Accessed January 25, 2012.
26. Pladevall M, Williams LK, Pott LA, Divine G, Xi H. Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27(12):2800-05. Available at: http://care.diabetesjournals.org/content/27/12/2800.full.pdf+html. Accessed January 25, 2012.
27. Riley GF, Levy JM, Montgomery, MA. Adverse selection in the Medicare prescription drug program. Health Aff (Millwood). 2009;28(6):1826-37.
28. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55. Available at: http://biomet.oxfordjournals.org/content/70/1/41.full.pdf+html. Accessed January 25, 2012.
29. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39(1):33-38.
30. Becker SO, Ichino A. Estimation of average treatment effects based on propensity scores. Stata J. 2002;2(4):358-77. Available at: http://www.statajournal.com/sjpdf.html?articlenum=st0026. Accessed January 25, 2012.
31. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-107.
32. Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following an acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54(4):387-98.
33. Austin PC. Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(1):62-67. Available at: http://circoutcomes.ahajournals.org/content/1/1/62.full.pdf+html. Accessed January 25, 2012.
34. Stockl KM, Tjioe D, Gong S, Stroup J, Harada AS, Lew HC. Effect of an intervention to increase statin use in Medicare members who qualified for a medication therapy management program. J Manag Care Pharm. 2008;14(6):532-40. Available at: http://www.amcp.org/data/jmcp/JMCPMaga_532-540.pdf.
35. Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular: a U.S. managed care study. Curr Med Res Opin. 2008;24(7):1987-2000.
36. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
37. Jing S, Naliboff A, Kaufman MB, Choy M. Descriptive analysis of mail interventions with physicians and patients to improve adherence with antihypertensive and antidiabetic medications in a mixed-model managed care organization of commercial and Medicare members. J Manag Care Pharm. 2011;17(5):355-66. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9731.
38. National Institutes of Health. National Heart, Lung, and Blood Institute. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Final report. NIH Publication No. 02-5215. September 2002. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf. Accessed January 25, 2012.